Foundation models, virtual cells, AI-designed molecules, and the companies putting them to work.

Medicine is shifting from managing disease to reprogramming it.

In oncology, that means engineered cells and synthetic circuits built to find and destroy tumors that chemotherapy and targeted drugs still cannot durably clear. In cardiometabolic disease, it means one-time gene edits and engineered therapies aimed at the mechanism itself, where GLP-1s and statins leave non-responders on lifelong management. In immunology, it means precision rather than blanket suppression, correcting immune dysfunction instead of muting it. In neurology, it means gene therapy, iPSC-derived cell replacement, and neural interfaces confronting the highest unmet need in medicine, where nearly every approved drug treats symptoms rather than neuronal loss. And underneath all of it, cellular reprogramming and stem-cell-derived replacement are targeting aging biology directly, not just the diseases it produces.

This theme follows the logic across every organ system, and presses on what matters: which of these are becoming medicine, and which are still biology?